Is there a relationship between aspirin responsiveness and clinical aspects of ischemic stroke?

Advances in Clinical and Experimental Medicine

Volumn 18, Issue 5, 2009, Pages 473-479

  Sobol, Anna Beata ^a   Mochecka, Alina ^a   Selmaj, Krzysztof ^a   Loba, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acetylsalicylic acid; Antiplatelet therapy; Aspirin responsiveness; Ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; COLLAGEN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANKIN SCALE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK;

EID: 72149114068     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321, 129-135.
2. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992, 268, 1292-1300.
3. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trial of antiplatelet therapy - I; prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308, 81-106. (Pubitemid 24052591)
4. Hovens MM, Snoep JD, Eikelboom JC, van der Bom JG, Mertens BJ, Huisman MV: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007,153, 175-181.
5. Patrono C: Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003, 1, 1710-1713.
6. Zimmermann N, Hohlfeld T: Clinical implications of aspirin resistance. Thromb Haemost 2008, 100, 379-390.
7. National Institute of Neurological Disorders and Stroke Ad Hoc Committee. Classification of cerebrovascular diseases III. Stroke 1990, 21, 637-676.
8. Rankin J: Cerebral vascular accidents in patients over the age of 60, I: general considerations. Scott Med J 1957, 2, 127-136.
9. Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schroer K, Siebler M: Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007, 24, 43-50. (Pubitemid 47026140)
10. Hung J, Lam JY, Lacoste L, Letchacovski G: Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995, 92, 2432-2436.
11. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004, 43, 979-984. (Pubitemid 38352975)
12. Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003, 42, 1059-1070. (Pubitemid 37186677)
13. Santos MT, Valles J, Lago A, Tembl J, Sanchez E, Moscardo A, Cosin J: Residual platelet thromboxane A2 and prothrombotic effects of erythrocyte are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008, 6, 615-621.
14. Maclouf J, Folco G, Patrono C: Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998, 79, 691-705. (Pubitemid 28163838)
15. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003, 112, 275-283. (Pubitemid 38373757)
16. Zytkiewicz M, Gielwanowska L, Wojtasińska E, Psuja P, Zawilska K: Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008, 11, 727-733.
17. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A: P1(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascu- lar injury. Circulation 2001, 104, 2666-2672.
18. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM: Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009, 101, 123-133.
19. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A: Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006, 113, 31-35.
20. Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006, 21 (suppl 1), 7-16. (Pubitemid 43254156)
21. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Magnat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25, 2331-2336.
22. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250, 63-66. (Pubitemid 36206686)
23. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM: Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischemic stroke and TIA. Platelets 2005, 16, 269-280. (Pubitemid 40943921)
24. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105, 1650-1655. (Pubitemid 34298607)
25. Englyst NA, Horsfield G, Kwan J, Byrne CD: Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008, 28, 1196-1203. (Pubitemid 351733359)
26. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators: Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49, 1982-1988. (Pubitemid 46694290)
27. Snoep JD, Hovens MM, Eikelboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 2007, 167, 1593-1599.
28. Krasopoulus G, Brister SJ, Beattie WS, Buchanan MR: Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336, 195-198.
29. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H: Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38, 353-356.
30. Patrono C, Rocca B: Aspirin: promise and resistance in the millennium. Arterioscler Thromb Vasc Biol. 2008, 28, 25-32.